Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers - PubMed (original) (raw)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al. Cancer Immunol Immunother. 2007 Aug.
Abstract
Purpose: The programmed death-1 (PD-1)/B7-H1 (also called PD-L1) pathway negatively regulates T cell activation and has been suggested to play an important role in regulating antitumor host immunity. To investigate the clinical significance of B7-H1 expression to the tumor grade and postoperative prognosis of patients with urothelial cancer, we analyzed the relationship between B7-H1 expression and various clinicopathological features and postoperative prognosis.
Experimental design: Sixty-five urothelial cancer cases were examined. B7-H1 expression in tumors and the numbers and phenotypes of tumor-infiltrating lymphocytes were evaluated by immunohistochemistry and flow cytometry.
Results: A substantial expression of B7-H1 was observed in all urothelial cancers investigated. Tumor specimens from patients with higher WHO grade or primary tumor classifications showed significantly higher percentages of tumor-associated B7-H1. Tumor-associated B7-H1 expression was significantly associated with a high frequency of postoperative recurrence and poor survival rate. Furthermore, multivariate analysis indicated that tumor-associated B7-H1 was more significant prognostic factor than WHO grade.
Conclusions: Our results demonstrate that the aberrant expression of B7-H1 in urothelial cancer is associated with aggressive tumors, suggesting a regulatory role of tumor-associated B7-H1 in antitumor immunity. Therefore, the manipulation of tumor-associated B7-H1 may become a beneficial target for immunotherapy in human urothelial cancer.
Figures
Fig. 1
Immunohistostaining with anti-B7-H1 mAb in urothelial cancer sections. Representative cases from WHO grade 3 with high B7-H1 expression (a), and grade 3 with low B7-H1 expression (b) tumors are shown. Bars 60 μm
Fig. 2
Association between the primary tumor (T) classification and B7-H1 expression in tumor cells, and the ratio of TILs. Tumor-associated B7-H1 expression is significantly associated with T classification (P = 0.031). The association between TILs and T classification had a tendency toward an inverse association, although the difference was not statistically significant (P = 0.084)
Fig. 3
A majority of TILs, including both CD4+ and CD8+ T cells, expressed PD-1 at high levels. On CD4+ TILs from tumor specimens 5, 6, and 11, the percentages of PD-1 expression were 77.50, 90.73, and 84.10%, respectively. On CD8+ TILs from tumor specimens 5, 6, and 11, the percentages of PD-1 expression were 95.17, 95.13, and 78.52%, respectively (broken line, stained with control mAb; regular line, stained with antibody against PD-1)
Fig. 4
Overall (a) and cause-specific (b) survival in 65 patients with urothelial cancer in relation to tumor B7-H1 status. The patients with high B7-H1 expression had a poorer prognosis than those with low B7-H1 expression (a P = 0.021 and b P = 0.041). c Recurrence-free survival in 62 patients who had no visible rest of tumor after surgery in relation to tumor B7-H1 status. The patients with high B7-H1 expression had a poorer prognosis than those with low B7-H1 expression (P = 0.026). P values were determined by the log-rank test
Similar articles
- Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Nukui A, Kamai T, Arai K, Kijima T, Kobayashi M, Narimatsu T, Kambara T, Yuki H, Betsunoh H, Abe H, Fukabori Y, Yashi M, Yoshida KI. Nukui A, et al. Cancer Immunol Immunother. 2020 May;69(5):689-702. doi: 10.1007/s00262-020-02499-7. Epub 2020 Feb 6. Cancer Immunol Immunother. 2020. PMID: 32030476 Free PMC article. - Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF. Xylinas E, et al. Eur J Surg Oncol. 2014 Jan;40(1):121-7. doi: 10.1016/j.ejso.2013.08.023. Epub 2013 Sep 18. Eur J Surg Oncol. 2014. PMID: 24140000 - High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q, Shou J, Ying J, Ling Y, Yu Y, Shen Z, Zhang Y, Li N, Shi Y, Zhou A. Zhong Q, et al. Future Oncol. 2021 Aug;17(22):2893-2905. doi: 10.2217/fon-2021-0092. Epub 2021 Jun 30. Future Oncol. 2021. PMID: 34189951 - Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
Thompson RH, Dong H, Kwon ED. Thompson RH, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. doi: 10.1158/1078-0432.CCR-06-1868. Clin Cancer Res. 2007. PMID: 17255298 Review. - The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Wen Y, Chen Y, Duan X, Zhu W, Cai C, Deng T, Zeng G. Wen Y, et al. Clin Exp Med. 2019 Nov;19(4):407-416. doi: 10.1007/s10238-019-00572-9. Epub 2019 Aug 12. Clin Exp Med. 2019. PMID: 31407099 Review.
Cited by
- Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.
Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM. Olislagers M, et al. Nat Rev Urol. 2024 Aug 2. doi: 10.1038/s41585-024-00914-7. Online ahead of print. Nat Rev Urol. 2024. PMID: 39095581 Review. - The Feasibility and Diagnostic Adequacy of PD-L1 Expression Analysis Using the Cytoinclusion Technique in Bladder Cancer: A Prospective Single-Center Study.
Di Gianfrancesco L, Montagner IM, Tormen D, Crestani A, Amodeo A, Corsi P, De Marchi D, Miglioranza E, Lista G, Simonetti F, Busetto GM, Maggi M, Marino F, Scapinello A, Porreca A. Di Gianfrancesco L, et al. J Clin Med. 2024 Jul 12;13(14):4072. doi: 10.3390/jcm13144072. J Clin Med. 2024. PMID: 39064112 Free PMC article. - Application of nitroxoline in urologic oncology - a review of evidence.
Tomczak WA, Krajewski W, Chorbińska J, Nowak Ł, Łaszkiewicz J, Grunwald K, Chełmoński A, Pisarski S, Szydełko T. Tomczak WA, et al. Contemp Oncol (Pozn). 2024;28(1):1-8. doi: 10.5114/wo.2024.139584. Epub 2024 May 19. Contemp Oncol (Pozn). 2024. PMID: 38800529 Free PMC article. Review. - The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer.
Larson AC, Doty KR, Solheim JC. Larson AC, et al. Cancer Med. 2024 May;13(10):e7287. doi: 10.1002/cam4.7287. Cancer Med. 2024. PMID: 38770637 Free PMC article. Review. - Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
Sanguedolce F, Falagario UG, Zanelli M, Palicelli A, Zizzo M, Busetto GM, Cormio A, Carrieri G, Cormio L. Sanguedolce F, et al. J Clin Med. 2024 Apr 10;13(8):2182. doi: 10.3390/jcm13082182. J Clin Med. 2024. PMID: 38673455 Free PMC article. Review.
References
- Tsujihashi H, Matsuda H, Uejima S, Akiyama T, Kurita T. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors. J Urol. 1988;140:890–894. - PubMed
- Tsujihashi H, Matsuda H, Uejima S, Akiyama T, Kurita T. Immunoresponse of tissue infiltrating lymphocytes in bladder tumors. J Urol. 1989;141:1467–1470. - PubMed
- Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med. 2003;81:281–287. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials